The pharmaceutical and biotech industries have experienced a surge of high-profile acquisitions and mergers in the first few months of the year, marking a notable trend in pharma M&A 2023. From Merck’s $11 billion acquisition of Prometheus Biosciences to Pfizer’s $43 billion purchase of Seagen, these deals highlight a focus on strengthening core assets and…
Pfizer to acquire Seagen for $43B
Pfizer and Seagen announced today that they entered into an agreement under which Pfizer acquires Seagen for $43 billion. The price of the acquisition comes to $229 in cash per Seagen share, totaling $43 billion. Both companies’ boards unanimously approved the transaction. Seagen develops antibody-drug conjugate (ADC) technology. Four of the 12 total FDA-approved and…
Pfizer considers bolstering its oncology standing through $30B Seagen acquisition
Big Pharma giant Pfizer (NYSE:PFE) is reportedly in talks to acquire Seagen (Nasdaq:SGEN). Founded in 1998, Seagen — formerly known as Seattle Genetics — helped pioneer a cancer therapy known as antibody drug conjugates that work like a guided missile attacking tumors with toxic agents. Last year, Segan installed David Epstein as its CEO after its…
Merck moves forward with Seagen acquisition plans
Executives from Merck & Co. (NYSE:MRK) and Seagen (Nasdaq:SGEN) are reportedly considering a $40 billion acquisition deal. Readington, New Jersey–based Merck has offered to spend about $200 per share for Seagen, according to The Wall Street Journal. Executives from the company aim to finalize the deal before Merck announces its Q2 earnings on July 28, according…
Merck reportedly mulling Seagen acquisition
Approximately one month after Seagen (Nasdaq:SGEN) CEO Clay Siegall resigned following a domestic abuse arrest, Merck & Co. (NYSE:MRK) is considering purchasing the company, according to WSJ. One potential hurdle is the possibility of increased antitrust enforcement from the DOJ and FTC focused on the pharmaceutical sector. To sidestep such risks, the two companies could enter a…
Seagen CEO Siegall resigns after domestic abuse arrest
Seagen (Nasdaq:SGEN) has announced that its CEO Clay Siegall has resigned following a domestic abuse arrest in April. Police charged Siegall with fourth-degree misdemeanor assault. He maintains his innocence. The company has named its lead independent director Felix Baker to assume the role of chair of the board of directors. Seagen Chief Medical Officer Dr.…